Skip to main content
logo
Ashland Inc. (ASH)
NYSE: ASH · Real-Time Price · USD
63.39
+3.16 (5.25%)
Feb 18, 2026, 4:00 PM EST - Market closed

Revenue by Geography

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14
United States Revenue
-464.00M624.00M
United States Revenue Growth
--25.64%-1.58%
International Revenue
-1.36B1.49B
International Revenue Growth
--8.66%-4.37%
Revenue (Total)
1.81B1.82B2.11B
Revenue (Total) Growth
-1.04%-13.68%-3.56%

Revenue

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14
Life Sciences Revenue
646.00M641.00M810.00M
Life Sciences Revenue Growth
0.78%-20.86%-6.79%
Personal Care Revenue
567.00M577.00M634.00M
Personal Care Revenue Growth
-1.73%-8.99%6.02%
Specialty Additives Revenue
498.00M511.00M572.00M
Specialty Additives Revenue Growth
-2.54%-10.66%-4.67%
Intermediates Revenue
134.00M137.00M144.00M
Intermediates Revenue Growth
-2.19%-4.86%-22.16%
Eliminations from Revenue
-39.00M-42.00M-47.00M
Revenue (Other)
-1.00M--
Revenue (Total)
1.81B1.82B2.11B
Revenue (Total) Growth
-1.04%-13.68%-3.56%

EBIT

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14
Life Sciences Operating Income
-259.00M-262.00M168.00M
Life Sciences Operating Income Growth
---2.33%
Personal Care Operating Income
90.00M90.00M73.00M
Personal Care Operating Income Growth
-23.29%40.38%
Specialty Additives Operating Income
-341.00M-338.00M-32.00M
Intermediates Operating Income
-8.00M29.00M
Intermediates Operating Income Growth
--72.41%-42.00%
Unallocated and Other Operating Income
-97.00M-273.00M-264.00M
Operating Income (Other)
5.00M--
Operating Income (Total)
-602.00M-775.00M-26.00M

EBITDA

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14
Life Sciences EBITDA
--187.00M229.00M
Life Sciences EBITDA Growth
---4.98%
Personal Care EBITDA
-155.00M152.00M
Personal Care EBITDA Growth
-1.97%10.95%
Specialty Additives EBITDA
--254.00M89.00M
Specialty Additives EBITDA Growth
--3.49%
Intermediates EBITDA
-21.00M42.00M
Intermediates EBITDA Growth
--50.00%-33.33%
Unallocated and Other EBITDA
--273.00M-264.00M
Operating Income (Total)
-602.00M-775.00M-26.00M

Key Performance Indicators

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16 Sep '15 Sep '14
Change in Sales Due to Volume
-98.00M1.00M
Change in Sales Due to Product Pricing/Mix
-46.00M-78.00M
Updated Dec 31, 2025. Data Source: Fiscal.ai.